Associated tags: Glioblastoma, Orphan drug, FDA, Food, Stanford University, Interleukin, Bifunctional, Therapy, Biskit, Cytokine, FastTrack, MDNA, Pharmaceutical industry, Patient, TSX, Immunotherapy, Cancer
Locations: NJ, USA, MA, BOSTON, EUROPE, AUSTRALIA, NEW YORK, FLORIDA, WASHINGTON, MOS, NI, ILLINOIS, TORONTO, ON, CA, SD, CANADA, EU, UNITED STATES
Patient,
PDAC,
Pembrolizumab,
Gene expression,
NK,
AACR,
MSI-H,
Cancer,
MDNA,
Pancreatic cancer,
Melanoma,
Radiation,
Observation,
TSX,
OTCQB,
Pharmaceutical industry Key findings from the monotherapy dose escalation portion of the ABILITY-1 study are consistent with a favorable safety profile.
Key Points:
- Key findings from the monotherapy dose escalation portion of the ABILITY-1 study are consistent with a favorable safety profile.
- In depth pharmacodynamic analyses showed potent and durable systemic immune response following MDNA11 administration with clear evidence of immune activation in the tumor microenvironment (TME).
- Increased expression of DNAM-1 (aka CD226), a potent regulator of anti-tumor immunity necessary for maintaining immune effector cell function.
- Combination escalation part of the ABILITY-1 study is enrolling patients with advanced solid tumors who progressed following earlier lines of treatment.
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1 Trial at the Sachs 10 th Annual Oncology Innovation Forum .
Key Points:
- TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1 Trial at the Sachs 10 th Annual Oncology Innovation Forum .
- The forum takes place on Friday, May 31st, 2024, as part of the clinical partnering and investment activities surrounding the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31st-June 4, 2024.
- Medicenna’s President and CEO, Dr. Fahar Merchant, will lead the Company’s presentation and be available for one-on-one meetings at the Sachs 10th Annual Oncology Innovation Forum as well as during the 2024 ASCO Annual Meeting.
- Details on the Company’s presentation at the Sachs 10th Annual Oncology Innovation Forum are as follows:
The Sachs Oncology Innovation Forum brings together thought leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street, to facilitate partnering, funding and investment.
TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement (the “Offering”). Medicenna intends to use the net proceeds from the Offering for further development of its MDNA11 program, advancement of its preclinical programs and general corporate purposes.
Key Points:
- TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement (the “Offering”).
- Medicenna intends to use the net proceeds from the Offering for further development of its MDNA11 program, advancement of its preclinical programs and general corporate purposes.
- The Offering is expected to close on or about April 30, 2024 and is subject to the approval of the TSX.
- “We are excited to announce the financial backing by RA Capital Management as a result of promising single-agent clinical activity of MDNA11, our differentiated IL-2 superkine,” said Dr. Fahar Merchant, President and CEO of Medicenna.
Retrieved on:
Wednesday, April 24, 2024
School,
OTCQB,
Abstract,
TSX,
MD,
Doctor of Philosophy,
GBM,
ASCO,
Duke University,
Rated R,
Patient,
Society,
MBA,
Annual general meeting,
MDNA,
University Challenge 2013–14,
Pharmaceutical industry TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.
Key Points:
- TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.
- The oral podium presentation will include new clinical data from the ongoing Phase 1/2 ABILITY-1 Study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®) in patients with advanced or metastatic solid tumors.
- Details of the podium presentation are as follows:
Title: “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors”
Details of the poster presentation are as follows:
Title: "Phase 2 Study of Bizaxofusp, an IL-4R Targeted Toxin Payload, in Nonresectable Recurrent GBM: Comparison of Overall Survival with Contemporaneous Eligibility-Matched and Propensity Score Balanced External Control Arm"
Presenter: Dr. John Sampson, MD, PhD, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery, School of Medicine, Duke University, Durham, North Carolina, USA
The full text of the published abstracts will be available on the 2024 ASCO Annual Meeting website on May 23rd, 2024 at 5:00 PM EDT.
Retrieved on:
Wednesday, April 10, 2024
Hypertelorism,
DLT,
Safety,
Radiation,
Pancreatic cancer,
TSX,
PR,
Cancer,
LFT,
Regulatory T cell,
Patient,
MDNA,
RDE,
Duodenal cancer,
Toxicity,
Melanoma,
BCC,
MCC,
AACR,
VLS,
MSI-H,
PD,
NK,
Combination therapy,
Pharmaceutical industry Key Points:
- March 22, 2024) include:
Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
- A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
- A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
- Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.
Toxicity,
PR,
Combination therapy,
VLS,
MSI-H,
PD,
LFT,
RDE,
Duodenal cancer,
Patient,
Hypertelorism,
Radiation,
MCC,
MDNA,
AACR,
TSX,
DLT,
Pancreatic cancer,
Safety,
Regulatory T cell,
Melanoma,
Cancer,
BCC,
NK,
Pharmaceutical industry Key Points:
- March 22, 2024) include:
Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
- A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
- A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
- Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.
TME,
Toxicity,
Metastasis,
Enzyme,
Survival,
Cleavage,
IL-2R,
Brain,
Patient,
Tumor microenvironment,
Mouse,
Breast,
Cancer,
Prostate,
Science,
MDNA,
AACR,
TSX,
Neoplasm,
Metalloproteinase,
Breast cancer,
Poster,
Medical imaging TORONTO and HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data on MDNA113, the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, an IL-13R⍺2 (Interleukin-13 receptor alpha2) specific superkine featuring unique masking and tumor targeting characteristics, were presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9th, 2024.
Key Points:
- Key findings presented at the conference include:
When not activated, MDNA113 shows reduced IL-2R agonism with no change to PD-1/PDL-1 blockade activity.
- MDNA113 selectively binds IL-13R⍺2 positive tumor cells in vitro, and durably accumulates (>7 days) in IL-13R⍺2 positive tumors in mice.
- Single neoadjuvant treatment with MDNA113 in a highly invasive orthotopic 4T1.2 breast cancer model significantly increases survival by preventing metastasis.
- It will be also available on the Scientific Presentations page of Medicenna’s website following the conclusion of the 2024 Annual Meeting of AACR.
TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
Key Points:
- TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
- Details on the presentation are as follows:
Webcast and replay information for this event will also be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/ .
- The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector.
- Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place in San Diego, CA from April 5-10, 2024.
Key Points:
- TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place in San Diego, CA from April 5-10, 2024.
- The Company will present an update from its Phase 1/2 ABILITY-1 Study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, the only long-acting, ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist in clinical development.
- In addition, pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 Superkine, will also be presented at the conference.
- Details for the abstracts and poster presentations are as follows:
Title: Results from Monotherapy Dose Escalation of MDNA11, a Long-acting IL-2 Superkine, in a Phase 1/2 Trial Show Evidence of Single-agent Activity in Advanced Solid Tumors
Following the conclusion of the AACR 2024 Meeting, a copy of the posters will be available on the “ Events and Presentations ” page of Medicenna’s website.
Retrieved on:
Wednesday, February 14, 2024
IPR,
Research,
CMO,
Decompression (diving),
PR,
Society,
Bifunctional,
MNP,
PRS,
Bank statement,
Melanoma,
OTCQB,
ICI,
Toronto Stock Exchange,
SITC,
CBV,
Annual general meeting,
European Medicines Agency,
Partnership,
BTD,
Highlight,
AACR,
Conference,
Safety,
Clinical trial,
Survival,
Neurology,
CFO,
EMA,
Enzyme,
MD,
ECA,
FDA,
TSX,
Cancer,
EDGAR,
Pembrolizumab,
Response,
MDNA,
SNO,
Patient,
Pharmaceutical industry Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.
Key Points:
- Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.
- Clinical update from the combination arm of the ABILITY-1 study evaluating MDNA11 in with KEYTRUDA® expected in H1 and H2 of 2024.
- Research and development expenses of $3.0 million were incurred during the quarter ended December 31, 2023, compared with $2.9 million incurred in the quarter ended December 31, 2022.
- General and administrative expenses of $1.8 million were incurred during the quarter ended December 31, 2023, compared with $2.0 million during the quarter ended December 31, 2022.
